Prognosis
Glaxo HIV Study Shows Injection More Effective Than Daily Pills
- Injection was 69% more effective in HIV prevention study
- Study involved 4,600 participants across 40 countries
This article is for subscribers only.
GlaxoSmithKline Plc’s ViiV Healthcare venture said a study showed its injection given every two months was 69% more effective in preventing HIV than daily pills.
A portion of the study evaluating cabotegravir stopped early following the results, according to a statement Monday from ViiV, majority-owned by Glaxo. It involved about 4,600 participants across more than 40 sites in North and South America, Asia, and Africa.